UK markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.42-0.01 (-0.16%)
As of 12:03PM EDT. Market open.
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2021
31/12/2020
31/12/2019
31/12/2018
Total revenue
67,487
78,447
227,547
148,364
0
Cost of revenue
26,934
14,217
2,392
-
-
Gross profit
40,553
64,230
225,155
-
-
Operating expenses
Research development
109,698
105,975
146,936
175,611
171,488
Selling general and administrative
137,593
184,985
199,615
65,854
33,097
Total operating expenses
247,291
290,960
346,551
241,465
204,585
Operating income or loss
-206,738
-226,730
-121,396
-93,101
-204,585
Interest expense
55,412
46,353
22,670
8,120
100
Total other income/expenses net
4,590
3,975
515
4,056
2,875
Income before tax
-257,560
-269,108
-143,551
-97,165
-201,810
Income from continuing operations
-257,560
-269,108
-143,551
-97,165
-201,810
Net income
-257,560
-269,108
-143,551
-97,165
-201,810
Net income available to common shareholders
-257,560
-269,108
-143,551
-97,165
-201,810
Basic EPS
-
-9.31
-5.23
-3.59
-7.54
Diluted EPS
-
-9.31
-5.23
-3.59
-7.54
Basic average shares
-
28,903
27,474
27,090
26,754
Diluted average shares
-
28,903
27,474
27,090
26,754
EBITDA
-
-222,143
-120,334
-88,726
-201,445